Literature DB >> 18261772

A comparison of the cell lines used in meningioma research.

Brian T Ragel1, William T Couldwell, David L Gillespie, Merideth M Wendland, Kum Whang, Randy L Jensen.   

Abstract

BACKGROUND: Immortal cell lines and cell lines derived from operative specimens transplanted into animal models are used in meningioma research. We address 2 criticisms of the mouse xenograft flank tumor model: Why are tumor induction rates derived from operative specimens low and inconsistent? Are flank tumors meningiomas?
METHODS: Meningioma cell cultures were processed for Giemsa-band karyotyping and flow cytometry. Mouse flank tumors induced subcutaneously were analyzed microscopically, immunohistochemically, and ultrastructurally. Giemsa-band studies identified meningiomas with simple karyotype (< or =1 chromosomal abnormality) or complex karyotype (multiple chromosomal abnormalities).
RESULTS: Cell cultures with complex karyotypes (IOMM-Lee, CH-157 MN, 2 operative specimens) grew rapidly in vitro and induced tumors in 49 (98%) of 50 animals. Meningioma cell cultures with simple karyotypes grew slowly in vitro and showed small, nongrowing tumors in mouse flanks (10/10). Meningioma flank tumors were vimentin-positive with ultrastructural features consistent with meningiomas. Cell cultures with complex karyotypes grew faster in cell culture and consistently induced flank tumors, unlike meningiomas with simple karyotypes.
CONCLUSIONS: Meningioma cell lines transplanted into flanks of nude mice exhibit microscopic, immunohistochemical, and ultrastructural features of meningiomas. The ease of monitoring tumor growth in the subcutaneous mouse flank model is its primary advantage, although we recognize an intracranial location is more biologically desirable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18261772     DOI: 10.1016/j.surneu.2007.06.031

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  16 in total

1.  Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas.

Authors:  Okay Saydam; Ozlem Senol; Tieneke B M Schaaij-Visser; Thang V Pham; Sander R Piersma; Anat O Stemmer-Rachamimov; Thomas Wurdinger; Saskia M Peerdeman; Connie R Jimenez
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

Review 2.  Advances in meningioma genetics: novel therapeutic opportunities.

Authors:  Matthias Preusser; Priscilla K Brastianos; Christian Mawrin
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

Review 3.  Meningioma mouse models.

Authors:  Michel Kalamarides; Matthieu Peyre; Marco Giovannini
Journal:  J Neurooncol       Date:  2010-08-24       Impact factor: 4.130

4.  Isolation and characterization of a population of stem-like progenitor cells from an atypical meningioma.

Authors:  Prakash Rath; Douglas C Miller; N Scott Litofsky; Douglas C Anthony; Qi Feng; Craig Franklin; Lirong Pei; Alan Free; Jimei Liu; Mingqiang Ren; Mark D Kirk; Huidong Shi
Journal:  Exp Mol Pathol       Date:  2010-12-17       Impact factor: 3.362

Review 5.  Brain-invasive meningiomas: molecular mechanisms and potential therapeutic options.

Authors:  Chaoying Qin; Meng Huang; Yimin Pan; Yuzhe Li; Wenyong Long; Qing Liu
Journal:  Brain Tumor Pathol       Date:  2021-04-26       Impact factor: 3.298

6.  Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function.

Authors:  Chunzhang Yang; Ashok R Asthagiri; Rajiv R Iyer; Jie Lu; David S Xu; Alexander Ksendzovsky; Roscoe O Brady; Zhengping Zhuang; Russell R Lonser
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-07       Impact factor: 11.205

7.  A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.

Authors:  Fares Nigim; Shin-Ichi Esaki; Michael Hood; Nina Lelic; Marianne F James; Vijaya Ramesh; Anat Stemmer-Rachamimov; Daniel P Cahill; Priscilla K Brastianos; Samuel D Rabkin; Robert L Martuza; Hiroaki Wakimoto
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

8.  Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model.

Authors:  Kenichiro Iwami; Atsushi Natsume; Masasuke Ohno; Hiroaki Ikeda; Junichi Mineno; Ikuei Nukaya; Sachiko Okamoto; Hiroshi Fujiwara; Masaki Yasukawa; Hiroshi Shiku; Toshihiko Wakabayashi
Journal:  Neuro Oncol       Date:  2013-03-03       Impact factor: 12.300

Review 9.  Therapeutic Hypothesis Testing With Rodent Brain Tumor Models.

Authors:  Derek A Wainwright; Craig M Horbinski; Rintaro Hashizume; C David James
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

10.  A novel component from citrus, ginger, and mushroom family exhibits antitumor activity on human meningioma cells through suppressing the Wnt/β-catenin signaling pathway.

Authors:  Arabinda Das; Rickey Miller; Philip Lee; Chrysanthe Alyssa Holden; Scott M Lindhorst; Jerry Jaboin; William A Vandergrift; Naren L Banik; Pierre Giglio; Abhay K Varma; Jeffery J Raizer; Sunil J Patel
Journal:  Tumour Biol       Date:  2015-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.